The estimated Net Worth of Pascal Deschatelets is at least $47.7 Million dollars as of 20 May 2024. Pascal Deschatelets owns over 24,500 units of Apellis Pharmaceuticals Inc stock worth over $43,748,928 and over the last 5 years he sold APLS stock worth over $2,095,220. In addition, he makes $1,821,230 as Co-Founder und Chief Operating Officer at Apellis Pharmaceuticals Inc.
Pascal has made over 38 trades of the Apellis Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 24,500 units of APLS stock worth $92,120 on 20 May 2024.
The largest trade he's ever made was exercising 234,411 units of Apellis Pharmaceuticals Inc stock on 12 February 2020 worth over $501,640. On average, Pascal trades about 19,962 units every 34 days since 2019. As of 20 May 2024 he still owns at least 1,140,483 units of Apellis Pharmaceuticals Inc stock.
You can see the complete history of Pascal Deschatelets stock trades at the bottom of the page.
Dr. Pascal Deschatelets Ph.D. serves as Co-Founder, Chief Operating Officer of the Company. Dr. Deschatelets also co-founded Potentia and served as its Chief Operating Officer from 2001 to September 2016 and is a cofounder of Revon. Dr. Deschatelets received his Ph.D. in organic chemistry from the University of Montreal and his post-doctoral training in the laboratory of Dr. George Whitesides at Harvard University.
As the Co-Founder und Chief Operating Officer of Apellis Pharmaceuticals Inc, the total compensation of Pascal Deschatelets at Apellis Pharmaceuticals Inc is $1,821,230. There are 4 executives at Apellis Pharmaceuticals Inc getting paid more, with Cedric Francois having the highest compensation of $4,267,180.
Pascal Deschatelets is 50, he's been the Co-Founder und Chief Operating Officer of Apellis Pharmaceuticals Inc since 2016. There are 7 older and 15 younger executives at Apellis Pharmaceuticals Inc. The oldest executive at Apellis Pharmaceuticals Inc is Gerald Chan, 69, who is the Independent Chairman of the Board.
Pascal's mailing address filed with the SEC is C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM, MA, 02451.
Over the last 6 years, insiders at Apellis Pharmaceuticals Inc have traded over $44,114,337 worth of Apellis Pharmaceuticals Inc stock and bought 1,248,415 units worth $38,006,599 . The most active insiders traders include Venture Investments Ltd Mor..., Cedric Francois und Pascal Deschatelets. On average, Apellis Pharmaceuticals Inc executives and independent directors trade stock every 6 days with the average trade being worth of $665,393. The most recent stock trade was executed by James George Chopas on 3 September 2024, trading 550 units of APLS stock currently worth $21,720.
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Apellis Pharmaceuticals Inc executives and other stock owners filed with the SEC include: